{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T17:42:12Z","timestamp":1767894132546,"version":"3.49.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T00:00:00Z","timestamp":1679356800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008746","name":"National Cancer Center","doi-asserted-by":"publisher","award":["2020-J-2"],"award-info":[{"award-number":["2020-J-2"]}],"id":[{"id":"10.13039\/100008746","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.lungcan.2023.03.001","type":"journal-article","created":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T11:13:21Z","timestamp":1678274001000},"page":"247-253","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Impact of ramucirumab pharmacokinetics in combination with docetaxel on the efficacy and survival in patients with advanced non-small cell lung cancer"],"prefix":"10.1016","volume":"178","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5487-0453","authenticated-orcid":false,"given":"Kazumasa","family":"Akagi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigehiro","family":"Yagishita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayu","family":"Ohuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiharu","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Takeyasu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Shinno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Okuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Goto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidehito","family":"Horinouchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noboru","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Mukae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Ohe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akinobu","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.lungcan.2023.03.001_b0005","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1200\/JCO.2009.23.7537","article-title":"Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2","volume":"28","author":"Spratlin","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"9944","key":"10.1016\/j.lungcan.2023.03.001_b0010","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(14)60845-X","article-title":"Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial","volume":"384","author":"Garon","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2023.03.001_b0015","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.lungcan.2016.07.019","article-title":"A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy","volume":"99","author":"Yoh","year":"2016","journal-title":"Lung Cancer"},{"issue":"12","key":"10.1016\/j.lungcan.2023.03.001_b0020","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S1470-2045(19)30634-5","article-title":"Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Nakagawa","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2023.03.001_b0025","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1634\/theoncologist.2019-0835","article-title":"Correlation between bevacizumab exposure and survival in patients with metastatic colorectal cancer","volume":"25","author":"Papachristos","year":"2020","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.lungcan.2023.03.001_b0030","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00280-018-3560-5","article-title":"Exposure\u2013response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer","volume":"82","author":"Smit","year":"2018","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.lungcan.2023.03.001_b0035","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/psp4.12224","article-title":"Pharmacokinetics of monoclonal antibodies","volume":"6","author":"Ryman","year":"2017","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.lungcan.2023.03.001_b0040","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/sj.bjc.6601242","article-title":"Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer","volume":"89","author":"Forrest","year":"2003","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lungcan.2023.03.001_b0045","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1111\/bcp.13403","article-title":"Population pharmacokinetic meta-analysis of ramucirumab in cancer patients","volume":"83","author":"O\u2019Brien","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.lungcan.2023.03.001_b0050","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2023.03.001_b0055","unstructured":"US Department of Health and Human Services, National Institutes of Health \u2013 National Cancer Institute, Common Terminology Criteria for Adverse Events (CTCAE), v.5.0, 2017. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm#ctc_50. (Accessed May 4, 2022)."},{"key":"10.1016\/j.lungcan.2023.03.001_b0060","unstructured":"JP MHLW. Guideline on bioanalytical method validation in pharmaceutical development 2013. http:\/\/www.nihs.go.jp\/drug\/BMV\/250913_BMV-GL_E.pdf. (Accessed April 1, 2022)."},{"key":"10.1016\/j.lungcan.2023.03.001_b0065","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/nrc3829","article-title":"Cancer cachexia: understanding the molecular basis","volume":"14","author":"Argil\u00e9s","year":"2014","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.lungcan.2023.03.001_b0070","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2023.03.001_b0075","doi-asserted-by":"crossref","unstructured":"K. Trobec, M. Kerec Kos, S. von Haehling, J. Springer, S.D. Anker, M. Lainscak, Pharmacokinetics of drugs in cachectic patients: a systematic review, PLOS ONE. 8 (2013) e79603. https:\/\/doi.org\/10.1371\/journal.pone.0079603.","DOI":"10.1371\/journal.pone.0079603"},{"key":"10.1016\/j.lungcan.2023.03.001_b0080","first-page":"2590","article-title":"Influence of whole body protein turnover rate on resting energy expenditure in patients with cancer","volume":"48","author":"Fearon","year":"1988","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.lungcan.2023.03.001_b0085","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/jcp.s1-6.1.13","article-title":"Turnover of plasma proteins","volume":"s1-6","author":"Jarnum","year":"1975","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.lungcan.2023.03.001_b0090","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/clpt.2011.328","article-title":"Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms","volume":"91","author":"Ord\u00e1s","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.lungcan.2023.03.001_b0095","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3892\/br.2013.54","article-title":"Elevated serum levels of vascular endothelial growth factor is effective as a marker for malnutrition and inflammation in patients with ovarian cancer","volume":"1","author":"Watanabe","year":"2013","journal-title":"Biomed. Rep."},{"key":"10.1016\/j.lungcan.2023.03.001_b0100","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1208\/s12248-012-9340-y","article-title":"Immunogenicity to therapeutic proteins: impact on PK\/PD and efficacy","volume":"14","author":"Chirmule","year":"2012","journal-title":"AAPS J."},{"issue":"1395","key":"10.1016\/j.lungcan.2023.03.001_b0105","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1098\/rstb.2000.0573","article-title":"Memory in the B\u2013cell compartment: antibody affinity maturation","volume":"355","author":"McMichael","year":"2000","journal-title":"Phil. Trans. R. Soc. Lond. B"},{"issue":"1","key":"10.1016\/j.lungcan.2023.03.001_b0110","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00228-021-03199-6","article-title":"Impacts of cachexia progression in addition to serum IgG and blood lymphocytes on serum nivolumab in advanced cancer patients","volume":"78","author":"Abe","year":"2022","journal-title":"Eur. J. Clin. Pharmacol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500223000867?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500223000867?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T13:07:52Z","timestamp":1759237672000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500223000867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":22,"alternative-id":["S0169500223000867"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.03.001","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of ramucirumab pharmacokinetics in combination with docetaxel on the efficacy and survival in patients with advanced non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}